Genomes and Genes
Summary: Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Publications279 found, 100 shown here
- Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
Cancer 116:1075-83. 2010..Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy.
- Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinomaPierre Yves Salaun
Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
Cancer 116:1053-8. 2010Significant antitumor effects were previously observed with radioimmunotherapy (RIT) using an anti-carcinoembryonic antigen (CEA) monoclonal antibody (F6) labeled with iodine-131 in medullary thyroid cancer (MTC)-bearing nude mice...
- 131I-tositumomab therapy as initial treatment for follicular lymphomaMark S Kaminski
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
N Engl J Med 352:441-9. 2005Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in ..
- Cancer radioimmunotherapyRobert M Sharkey
Garden State Cancer Center, Belleville, NJ 07109, USA
Immunotherapy 3:349-70. 2011Targeting of radionuclides with antibodies, or radioimmunotherapy, has been an active field of research spanning nearly 50 years, evolving with advancing technologies in molecular biology and chemistry, and with many important preclinical ..
- Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograftFrançoise Kraeber-Bodéré
INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
J Nucl Med 51:624-31. 2010A significant antitumor effect was previously observed with radioimmunotherapy using anti-carcinoembryonic antigen (131)I-F6 monoclonal antibody in medullary thyroid cancer-bearing nude mice...
- Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude miceBirgit Pfost
Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
J Nucl Med 50:1700-8. 2009....
- Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I studyHakan Andersson
Department of Oncology, University of Gothenburg, Gothenburg, Sweden
J Nucl Med 50:1153-60. 2009..The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity...
- Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imagingAlexander B Stillebroer
Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
J Nucl Med 53:82-9. 2012This study aimed to estimate the radiation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG250...
- Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomasL F Porrata
Leukemia 21:2554-6. 2007
- Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in miceRafke Schoffelen
Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
J Nucl Med 51:1780-7. 2010Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies in combination with a radiolabeled peptide reduces the radiation dose to normal tissues, especially the bone marrow...
- High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphomaFranck Morschhauser
Service des Maladies du Sang, Centre Hospitalier Regional, L Universitaire de Lille, France
J Clin Oncol 28:3709-16. 2010Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL).
- Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasisKarin Knogler
Center for Radiopharmaceutical Science, ETH PSI USZ, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
Clin Cancer Res 13:603-11. 2007..We examined the tumor-targeting and therapeutic effects of (67)Cu-labeled single amino acid mutant forms of anti-L1 monoclonal antibody chCE7 in nude mice with orthotopically implanted SKOV3ip human ovarian carcinoma cells...
- Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control groupTorsten Liersch
Department of General Surgery, University of Gottingen, Gottingen, Germany
Ann Surg Oncol 14:2577-90. 2007We tested whether adjuvant radioimmunotherapy (RAIT) given after R0 resection of liver metastases (LM) of colorectal cancer is safe and can improve survival...
- Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodiesR O Dillman
Medical and Scientific Director, Hoag Cancer Center, Newport Beach, CA 92658, USA
Clin Exp Med 6:1-12. 2006..Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma,..
- Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patientsMichael F Leahy
Department of Hematology, The University of Western Australia, Fremantle Hospital, Fremantle, Australia
Blood 117:45-52. 2011b>Radioimmunotherapy of indolent non-Hodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is ..
- Radioimmunotherapy and colorectal cancerM J Koppe
Department of Surgery, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
Br J Surg 92:264-76. 2005Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour-associated antigens in the treatment of non-Hodgkin's lymphoma, therapeutic success in solid tumours has been modest...
- Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceM S Kaminski
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0936, USA
Blood 96:1259-66. 2000CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL)...
- Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationshipNathan Lawrentschuk
Department of Surgery, University of Melbourne, Australia
BJU Int 97:916-22. 2006
- Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphomaB Esmaeli
Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Ann Oncol 20:709-14. 2009..To determine the efficacy and side-effects of (90)Y ibritumomab tiuxetan (Zevalin) as front-line treatment in patients with early-stage extranodal indolent lymphoma of the ocular adnexa (orbit, conjunctiva, or eyelid)...
- The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomabRichard L Wahl
Division of Nuclear Medicine, Johns Hopkins Medical Institutions, Department of Radiology, Baltimore, MD 21287 0817, USA
Semin Oncol 30:31-8. 2003b>Radioimmunotherapy (RIT) is a promising emerging therapy for non-Hodgkin's lymphoma and may ultimately prove useful in the treatment of other tumors...
- Clinical radioimmunotherapy--the role of radiobiologyJean Pierre Pouget
Direction de la RadioProtection de l Homme, Institut de Radioprotection et de Surete Nucleaire, Fontenay aux Roses, F 92262, France
Nat Rev Clin Oncol 8:720-34. 2011Conventional external-beam radiation therapy is dedicated to the treatment of localized disease, whereas radioimmunotherapy represents an innovative tool for the treatment of local or diffuse tumors...
- PET/CT Imaging and Radioimmunotherapy of Prostate CancerKirsten Bouchelouche
PET and Cyclotron Unit, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, Denmark
Semin Nucl Med 41:29-44. 2011..Prostate cancer represents an attractive target for radioimmunotherapy (RIT) for several reasons, including pattern of metastatic spread (lymph nodes and bone marrow, sites with ..
- Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapyM G Steffens
Department of Urology, University Hospital Nijmegen, The Netherlands
Cancer Res 59:1615-9. 1999..the intratumoral distribution of the antibody is highly heterogeneous, which may limit the efficacy of radioimmunotherapy. A number of highly dynamic physiological factors have been postulated that may contribute to heterogeneous ..
- Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclideEric Frampas
Centre de Recherche en Cancérologie Nantes Angers, Universite de Nantes, INSERM, UMR 892, 8 quai Moncousu, BP 70721, 44007 Nantes Cedex 1, France
Eur J Nucl Med Mol Imaging 38:2153-64. 2011We investigated influences of pretargeting variables, tumor location, and radionuclides in pretargeted radioimmunotherapy (PRIT) as well as estimated tumor absorbed doses.
- Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastasesGabie M De Jong
Division of Abdominal and Oncological Surgery, Department of Surgery, Radboud University Nijmegen Medical Centre, Geert Grooteplein zuid 10, Nijmegen, The Netherlands
Ann Surg 253:336-41. 2011The aim of this study was to test the hypothesis that adjuvant radioimmunotherapy (RIT) prevents recurrent liver metastases and/or results in improved survival after tumorectomy in an experimental model.
- Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapyAurore Oudoux
Nuclear Medicine, University Hospital, 44093 Nantes, France
J Clin Endocrinol Metab 92:4590-7. 2007..Patients with progressive medullary thyroid carcinoma (MTC) undergo multiple imaging procedures for diagnosis of relapse and staging...
- Pretargeted radioimmunotherapy of cancer: progress step by stepOtto C Boerman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
J Nucl Med 44:400-11. 2003To enhance the therapeutic efficacy of radioimmunotherapy of cancer, several pretargeting strategies have been developed...
- Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapyRobert M Sharkey
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ, USA
Semin Nucl Med 40:190-203. 2010..However, for many other cancers, radioimmunotherapy has been ineffective, being limited by prolonged exposure to the highly radiosensitive bone marrow...
- Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal originGabie M De Jong
Department of Surgery, Division of Abdominal and Oncological Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Ann Surg Oncol 16:2065-73. 2009..The aim of the present study was to assess the efficacy of radioimmunotherapy (RIT) with a radiolabeled monoclonal antibody (mAb) to treat experimental colorectal liver metastases.
- High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer modelT M Behr
Department of Nuclear Medicine, Georg August University, Gottingen, Germany
Cancer Res 59:2635-43. 1999Recent studies suggest that radioimmunotherapy (RIT) with high-linear energy transfer (LET) radiation may have therapeutic advantages over conventional low-LET (e.g., beta-) emissions...
- Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancerJing Chen
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No 1095, Jiefang Dadao, 430030 Wuhan, People s Republic of China
Cancer Lett 231:169-75. 2006..The results suggests that the radioimmunotherapy of intratumoral injection of 131I-Sc-7269-DMN may be safe and efficient for the treatment of liver cancer...
- Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman
Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
Eur J Nucl Med 27:766-77. 2000..The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or T(1/2), reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population...
- A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee
Division of Hematology and Hemapoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
Blood 106:2896-902. 2005..We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-dose etoposide and cyclophosphamide without an increase in transplant-related toxicity or delayed engraftment...
- Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapyTim M Illidge
School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK
Blood 113:1412-21. 2009..of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown...
- 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospitalJ Harvey Turner
Department of Nuclear Medicine, Fremantle Hospital and Department of Medicine, The University of Western Australia, Fremantle, Western Australia, Australia
Cancer Biother Radiopharm 18:513-24. 2003In order to increase the availability and affordability of radioimmunotherapy of refractory or relapsed non-Hodgkins lymphoma, we developed and evaluated radioiodinated rituximab in an ongoing physician-sponsored Phase II Clinical Trial...
- Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparisonBarry W Wessels
Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio
J Nucl Med 45:1725-33. 2004..In this work, we have analyzed reported marrow dosimetry results from radioimmunotherapy trials and recalculated marrow absorbed doses at a central facility using a standard blood model with ..
- Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patientsStefanie Sauer
Department of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
Blood 113:2265-74. 2009..In 2 relapsed Hodgkin lymphoma patients(131)I-L19SIP radioimmunotherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma ..
- Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicityJörgen Elgqvist
Department of Radiation Physics, The Sahlgrenska Academy at Goteborg University, SE 413 45 Goteborg, Sweden
Nucl Med Biol 33:1065-72. 2006The aim of this study was to investigate the therapeutic efficacy and myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice...
- Radioimmunotherapy of lymphoma: Bexxar and ZevalinStanley J Goldsmith
Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Cornell College of Medicine, New York, NY 10065, USA
Semin Nucl Med 40:122-35. 2010b>Radioimmunotherapy is a form of targeted radionuclide therapy that uses a monoclonal antibody to deliver localized radiation...
- A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomasTim Meyer
UCL Cancer Institute, University College London, United Kingdom
Clin Cancer Res 15:4484-92. 2009In preclinical models, radioimmunotherapy with (131)I-A5B7 anti-carcinoembryonic antigen (CEA) antibody ((131)I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone...
- Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphomaRuby F Meredith
Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL, USA
Int J Radiat Oncol Biol Phys 66:S15-22. 2006..Two radioimmunotherapy agents that target the CD20 antigen, (131)I-tositumomab and (90)Y-ibritumomab tiuxetan, have been approved ..
- Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomographyCaroline Bodet-Milin
Nuclear Medicine Department, University Hospital, Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
Haematologica 93:390-7. 2008The study aimed to evaluate FDG-PET imaging for early prediction of response to radioimmunotherapy in patients with non-Hodgkin's lymphoma.
- Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapyScott S Graves
NeoRx Corporation, Seattle, Washington 98119 4114, USA
Clin Cancer Res 9:3712-21. 2003Pretarget radioimmunotherapy (RIT) is a multistep strategy for cancer therapy designed to reduce nontarget organ exposure by uncoupling the tumor targeting moiety from the radioactive ligand...
- Perspectives of molecular imaging and radioimmunotherapy in lymphomaAndrei Iagaru
Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H 0101, Stanford, CA 94305 5427, USA
Radiol Clin North Am 46:243-52, viii. 2008..uses of 18F Fluoro-2-Deoxyglucose (18F FDG) PET and PET/CT for evaluation of lymphoma patients and use of radioimmunotherapy in lymphoma...
- Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma modelSophie E Eriksson
Department of Oncology, Lund University, Sweden
Cancer Biother Radiopharm 27:134-40. 2012Fractionation is generally used as a mean to improve radioimmunotherapy (RIT)...
- Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvementPierre Yves Salaun
Nuclear Medicine Department, University Hospital and ICO Gauducheau Cancer Institute, IRCNA, Cancer Research Center, Universite de Nantes, INSERM, UMR 892, Nantes, France
J Nucl Med 53:1185-92. 2012..This prospective phase II multicenter trial evaluated the efficacy and safety of anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metastatic MTC patients and also how serum biomarker DTs correlate with ..
- Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites modelEmma Y Song
Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, UK
Cancer Biol Ther 7:76-80. 2008..The aim of this study was to investigate the effect of targeted alpha therapy (TAT) for the control of ascites in an OC ascites mouse model; the biodistribution of (213)Bi-C595 and its long term toxicity...
- Radioimmunotherapy with 131I-rituximab: what we know and what we don't knowMalik E Juweid
Cancer Biother Radiopharm 18:489-95. 2003
- Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma: a study in safetyPhillipe J Calais
Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia
Clin Nucl Med 37:732-7. 2012This study aimed to establish the safety of outpatient 131I-rituximab radioimmunotherapy by measuring the radiation exposure of hospital staff, carers, and members of the public and by estimating the environmental impact of radioactive ..
- Radioimmunotherapy: optimizing delivery to solid tumorsVineeth Rajkumar
UCL Cancer Institute, University College London, 72 Huntley St, London WCIE 6BT, UK
Ther Deliv 2:567-72. 2011b>Radioimmunotherapy (RIT) is a cancer treatment that exploits the specific targeting capability of monoclonal antibodies to deliver cytotoxic radionuclides to antigen-expressing tumor cells or stromal targets...
- (212)Pb@C(60) and its water-soluble derivatives: synthesis, stability, and suitability for radioimmunotherapyMichael D Diener
TDA Research Incorporated, 12345 West 52nd Avenue, Wheat Ridge, Colorado 80033 and Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37831 6229, USA
J Am Chem Soc 129:5131-8. 2007Fullerenes could potentially play a valuable role in radioimmunotherapy by more stably encapsulating radionuclides, especially where conventional chelation chemistry is inadequate due to the physical and/or chemical properties of the ..
- Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experienceD R Colnot
Department of Otolaryngology-Head and Neck Surgery, University Hospital Vrije Universiteit, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Head Neck 23:559-65. 2001..An effective adjuvant therapy is required for these patients. Among novel approaches is radioimmunotherapy, in which monoclonal antibodies (MAbs) are used for selective delivery of radiation to tumor cells...
- Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphomaKevin J Hamblett
Department of Bioengineering, Medicine, University of Washington, Seattle, Washington 98195, USA
Bioconjug Chem 16:131-8. 2005One pretargeting approach to cancer radioimmunotherapy utilizes an antibody-streptavidin conjugate that is first localized to the tumor...
- Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapyJeffrey N Bryan
Department of Veterinary Medicine and Surgery, University of Missouri Columbia, USA
Cancer Biol Ther 11:1001-7. 2011We previously described a two-antibody model of (64)Cu radioimmunotherapy to evaluate low-dose, solid-tumor response...
- Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphomaJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Clin Lymphoma 5:S22-6. 2004Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing ..
- Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazineRhona Stein
Garden State Cancer Center, Belleville, New Jersey 07109, USA
Cancer 94:51-61. 2002..the efficacy of chemotherapy for medullary thyroid carcinoma (MTC), we evaluated the effect of combining radioimmunotherapy (RAIT) with 90Y-anticarcinoembryonic antigen (CEA) monoclonal antibody MN-14 and chemotherapy in nude mice ..
- Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference reportThomas E Witzig
Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 52:1188-99. 2011b>Radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan or (131)I-tositumomab combines a radiation-emitting radionuclide with an antibody targeting CD20 to treat B-cell non-Hodgkin lymphoma...
- Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetryCecilia Hindorf
Department of Radiation Physics, Lund University, Lund, Sweden
Cancer 94:1235-9. 2002The method for red marrow dosimetry in radioimmunotherapy, in the absence of specific activity uptake in red marrow, is based on the activity measured in the blood or plasma...
- Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patientsCecilia Hindorf
Department of Medical Radiation Physics, Jubileum Institute, Lund University, SE 221 85 Lund, Sweden
Clin Cancer Res 9:4003S-6S. 2003..internal dosimetry protocols that assume a fixed tumor mass in lymphoma patients, using a fractionated radioimmunotherapy schedule and using a single infusion...
- Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphomaThomas Cazaentre
Service de Médecine Nucléaire et Imagerie Fonctionnelle, CHU Lille, 59000, Lille, France
Eur J Nucl Med Mol Imaging 37:494-504. 2010b>Radioimmunotherapy (RIT) is a new treatment option for patients with non-Hodgkin lymphoma (NHL). Response to RIT currently remains difficult to predict using conventional prognostic factors and could be refined using functional imaging...
- Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumabZhaofei Liu
Medical Isotopes Research Center, Peking University, 38 Xueyuan Road, Beijing 100191, China
Mol Cancer Ther 9:2297-308. 2010..Here, we report for the first time the radioimmunotherapy (RIT) of EGFR-positive human head and neck cancer in a nude mouse model using pure beta(-) emitter (90)Y-..
- Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nucleiY Kvinnsland
Department of Nuclear Medicine, The Norwegian Radium Hospital, 0310, Norway
Radiat Res 155:288-96. 2001..The magnitudes of the differences were found to be a function of the fractions of mean specific energy delivered by surrounding activity and by activity bound to the cells...
- Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopeniaRussell Schilder
Fox Chase Comprehensive Cancer Center, Philadelphia, PA 1911 2412, USA
Cancer Biother Radiopharm 19:478-81. 2004..Patients received a single course of ibritumomab tiuxetan radioimmunotherapy, with 90Y ibritumomab tiuxetan administered at 0.3 mCi/kg (compared to a standard dose of 0.4 mCi/kg)...
- High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot studyThomas M Behr
Department of Nuclear Medicine, Georg August University of Gottingen, Gottingen, Germany
Cancer 94:1363-72. 2002..been used successfully as a target molecule for conventional low-dose, as well as high-dose, myeloablative radioimmunotherapy (RIT) of B-cell non-Hodgkin lymphoma (NHL)...
- Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 118:703-11. 2011Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)-streptavidin (SA) conjugate and DOTA-biotin labeled with β-emitting radionuclides has been explored as a strategy to decrease relapse and toxicity...
- Pretargeted radioimmunotherapy for B-cell lymphomasDamian J Green
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
Clin Cancer Res 13:5598s-5603s. 2007..We have investigated the potential utility of pretargeted radioimmunotherapy using monoclonal antibody-streptavidin, immunoconjugates, and fusion proteins in combination with N-..
- Doubly radiolabeled liposomes for pretargeted radioimmunotherapyM Mougin-Degraef
Département de Recherche en Cancérologie, INSERM, U601, Universite de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France
Int J Pharm 344:110-7. 2007The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters...
- A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignanciesYukang Lin
The Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue North, Seattle, WA 98109, USA
Cancer Res 66:3884-92. 2006..We now show the superiority of pretargeted radioimmunotherapy (PRIT) compared with conventional radioimmunotherapy using a recombinant tetravalent single-chain Ab-..
- Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicityShankar Vallabhajosula
Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
Clin Cancer Res 11:7195s-7200s. 2005Bone marrow is the dose-limiting organ in radioimmunotherapy. Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose...
- Editorial: what ails solid tumor radioimmunotherapy?Chaitanya Divgi
Cancer Biother Radiopharm 21:81-4. 2006
- Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotinZhengsheng Yao
Department of Nuclear Medicine, Warren G Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:3137-46. 2004The use of an alpha emitter for radioimmunotherapy has potential advantages compared with beta emitters...
- Engineered single chain antibody fragments for radioimmunotherapyA Huhalov
Cancer Research UK Imaging and Targeting Group, Department of Oncology, Royal Free and University College Medical School, Royal Free Campus London, United Kingdom
Q J Nucl Med Mol Imaging 48:279-88. 2004An ideal molecule to deliver radioimmunotherapy (RIT) would be target specific and have prolonged residence time at high concentrations in the tumour with rapid clearance from normal tissues. It would also be non-immunogenic...
- Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infectionEkaterina Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
J Infect Dis 193:1427-36. 2006The usefulness of radioimmunotherapy (RIT) for infectious diseases was recently demonstrated for several fungal and bacterial infections, but the mechanisms by which RIT is effective against microbes are uncertain.
- High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human Carol M Richman
University of California Davis, Sacramento, California 95817, USA
Clin Cancer Res 11:5920-7. 2005Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach...
- Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopesEkaterina Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, 1695A Eastchester Road, Bronx, NY 10461, USA
J Nucl Med 45:313-20. 2004..One novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal antibodies (mAbs) labeled with radionuclides...
- Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine modelsE Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Antimicrob Agents Chemother 48:1004-6. 2004We evaluated acute hematological and long-term pulmonary toxicity of radioimmunotherapy in murine models of Cryptococcus neoformans infection...
- Feasibility of radioimmunotherapy of experimental pneumococcal infectionE Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Antimicrob Agents Chemother 48:1624-9. 2004..We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice...
- Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trialsZhi Nan Chen
Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi an, China
Int J Radiat Oncol Biol Phys 65:435-44. 2006..We developed iodine (131I) metuximab injection (Licartin), a novel 131I-labeled HAb18G/CD147-specific monoclonal antibody Fab'2 fragment, and evaluated its safety, pharmacokinetics, and clinical efficacy on HCC in Phase I/II trials...
- Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacyJason L J Dearling
Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, University College London, London, UK
Clin Cancer Res 13:1903-10. 2007The efficacy of solid tumor radioimmunotherapy is reduced by heterogeneous tumor distribution of the radionuclide, with dose mainly deposited in the normoxic region and by the relative radioresistance of hypoxic tumor cells...
- The radiation biology of radioimmunotherapyK L Dixon
Department of Physics, The University of British Colombia, Canada
Nucl Med Commun 24:951-7. 2003The treatment of cancer is a wide and varied field, encompassing many methods and modalities. Radioimmunotherapy is a technique which utilizes the ablative properties of radiation by delivering radioactive particles directly to the tumour ..
- Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell
Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, California 95816
Clin Cancer Res 7:1561-8. 2001..b>Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer...
- Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infectionRuth A Bryan
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
J Infect Dis 202:633-7. 2010b>Radioimmunotherapy (RIT) prolongs the survival of mice infected with Cryptococcus neoformans. To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice intravenously with either nonmelanized or melanized C...
- Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiformeAnand Veeravagu
Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305 5484, USA
Clin Cancer Res 14:7330-9. 2008..The purpose of this study was to evaluate the efficacy of a novel 90Y-Abegrin radioimmunotherapeutic agent in murine xenograft glioblastoma models with noninvasive in vivo molecular imaging modalities...
- Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6ROBERT T O'DONNELL
Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA
Prostate 50:27-37. 2002..55 MBq;150 microCi) has resulted in durable responses. To make radioimmunotherapy (RIT) more effective, the radiation-enhancing drugs Taxol (paclitaxel) and Taxotere (docetaxel) were tested ..
- Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cellsRuth A Bryan
Departments of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Antimicrob Agents Chemother 53:1679-82. 2009We investigated the utility of radioimmunotherapy (RIT) in the treatment of experimental cryptococcal infection with high-inoculum and the possibility of RIT treatment selecting for fungal cells with radiation-resistant phenotypes...
- Model prediction of treatment planning for dose-fractionated radioimmunotherapySui Shen
Department of Radiation Oncology, University of Alabama at Birmingham, 35294, USA
Cancer 94:1264-9. 2002Clinical trials of radioimmunotherapy (RIT) often use dose fractionation to reduce marrow toxicity. The dosing scheme can be optimized if marrow and tumor cell kinetics following radiation exposure are known.
- Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinomaZhao Chong Zeng
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, P R China
Eur J Nucl Med Mol Imaging 29:1657-68. 2002It has previously been observed in animal studies that, at equivalent doses, radioimmunotherapy (RIT) is 2.5 times more effective than multiple fractions of external beam radiation therapy (EBRT) in inhibiting tumour growth...
- FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric studyE Lopci
Nuclear Medicine Department, University Hospital S Orsola Malpighi, Bologna, Italy
Ann Oncol 21:1877-83. 2010..is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL)...
- Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomasJohn M Pagel
Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109, USA
Blood 101:2340-8. 2003..These lymphoma xenograft data suggest that pretargeted radioimmunotherapy using either anti-CD20 or anti-CD45 conjugates is highly effective and minimally toxic.
- Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumorsFares Al-Ejeh
Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, South Australia, Australia
PLoS ONE 4:e4630. 2009..inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 ((90)Y)-radio-conjugates of a monoclonal antibody, ..
- Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo
Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
Cancer 94:1332-48. 2002..used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies...
- A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastasesYonggang Lv
Department of Biomedical Engineering, The City College of New York, New York, New York 10031, USA
J Nucl Med 50:1324-31. 2009b>Radioimmunotherapy can effectively treat leptomeningeal metastases when radiolabeled antibodies are administered into the cerebrospinal fluid (CSF)...
- Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancerA Murray
Department of Medical Physics, Medical School, Queen's Medical Centre, Nottingham, United Kingdom
J Nucl Med 42:726-32. 2001..MUC1 mucin is overexpressed on bladder tumors and represents a useful target for radioimmunoscintigraphy and radioimmunotherapy. We report on the production and initial tracer studies of a 188Re-antibody complex directed against this ..
- Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6Rébécca Phaeton
Department of Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY, USA
Cancer Biol Ther 10:1041-7. 2010..b>Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated ..
- Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphomaPeter L Roberson
Department of Radiation Oncology, University of Michigan, 519 W William St, Argus I, Ann Arbor, MI 48103 4943, USA
Eur J Nucl Med Mol Imaging 38:874-83. 2011..Treatment with tositumomab and (131)I-tositumomab anti-CD20 radioimmunotherapy (BEXXAR) yields a cold antibody antitumor response (cold protein effect) and a radiation response...
- Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cellsClaudia Friesen
University Children s Hospital, Prittwitzstrasse 43, 89075 Ulm, Germany
Eur J Nucl Med Mol Imaging 30:1251-61. 2003Beta-irradiation used for systemic radioimmunotherapy (RIT) is a promising treatment approach for high-risk leukaemia and lymphoma...
- Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HITAlexandra D Jensen
Dept of Radiation, Oncology INF, Heidelberg Germany
BMC Cancer 11:182. 2011..Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and ..
- Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshopPier Luigi Zinzani
Institute of Hematology and Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
Eur J Cancer 44:366-73. 2008..This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas...
- The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in miceRébécca Phaeton
Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA
Cancer 116:1067-74. 2010..The authors of this report recently demonstrated the efficacy of radioimmunotherapy (RIT) targeting viral oncoprotein E6 in the treatment of experimental cervical cancer...
- Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomasW Debinski
Department of Surgery, Pennsylvania State University, College of Medicine, Hershey 17033 0850, USA
Clin Cancer Res 5:3143s-3147s. 1999....
- Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8K Kramer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Pediatr Oncol 35:716-8. 2000..Intrathecal antibody-based targeted therapies may have clinical potential for patients with leptomeningeal (LM) cancer...
- Targeted liposomal radiotherapy of malignant mesotheliomaJiang He; Fiscal Year: 2010..Highly selective tumor location and targeting are needed. Our long term goal is to develop effective radioimmunotherapy (RIT) for human cancers by marrying radiotherapy with nanotechnology...
- Bispecific Antibody Engineering for AML RITOLIVER W contact PRESS; Fiscal Year: 2010..of this research proposal is to maximize the cure rate of AML using a novel approach employing pretargeted radioimmunotherapy (PRIT) with genetically engineered bispecific antibodies...
- Foundations of Pretargeted RadioimmunotherapyKARL WITTRUP; Fiscal Year: 2009Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
- CD45 Pretargeted Radioimmunotherapy for AMLOliver W Press; Fiscal Year: 2010..The objective of this research proposal is to improve the cure rate of AML using radioimmunotherapy (RIT) targeting the CD45 cell antigen...
- NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALSDonald Buchsbaum; Fiscal Year: 2001..The experiments described in this application will provide answers to these questions. These studies would establish the rationale for human clinical RIT trials in patients with Jp. cancer using HuCC49ACH2. ..
- NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIESSTEVEN TREON; Fiscal Year: 2004..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
- Hematopoietic Cell Transplantation for Hematologic MalignanciesStephen Forman; Fiscal Year: 2007..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
- PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMASOliver W Press; Fiscal Year: 2010..The objective of this research proposal is to optimize radioimmunotherapy (RIT) of B cell lymphomas utilizing pretargeting amplification strategies to improve the efficacy and ..
- BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATIONClaude Meares; Fiscal Year: 1999..Antibodies have been conjugated to metal chelates for radioimmunotherapy and studied extensively in recent years, and are in clinical trials at various stages...
- TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPYEdward A Neuwelt; Fiscal Year: 2010..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
- TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPYEdward Neuwelt; Fiscal Year: 2009..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
- TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPYEdward Neuwelt; Fiscal Year: 2009..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
- Radioimmunotherapy of Acute LeukemiaEneida Nemecek; Fiscal Year: 2007....
- Foundations of Pretargeted RadioimmunotherapyKARL D WITTRUP; Fiscal Year: 2010Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
- Novel glutamate conjugates for radiotargeting PSMAJohn Babich; Fiscal Year: 2004The development of novel approaches for radioimmunoimaging and radioimmunotherapy is driven by the high incidence and mortality rate associated with prostate cancer in the United States...
- PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMASOliver Press; Fiscal Year: 2001..pretargeting amplification strategies to improve the efficacy and decrease the toxicity of conventional radioimmunotherapy (RAIT)...
- Improved Tumor Radiotherapy by MORF pretargetingDonald Hnatowich; Fiscal Year: 2005Despite several decades of effort, conventional radioimmunotherapy of hematopoietic and especially solid tumors is still providing marginal results. As such, alternative methods of treating these diseases are needed...